One Grand Central Place
Suite 4600 60 East 42nd Street
New York, NY 10165
United States
212 949 4319
https://www.pavmed.com
Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 25
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Lishan Aklog M.D. | Chairman & CEO | 686.3k | N/A | 1966 |
Mr. Dennis M. McGrath CPA | Pres, CFO & Corp. Sec. | 517.7k | N/A | 1957 |
Dr. Brian J. deGuzman M.D. | Chief Medical Officer & Exec. VP of Clinical Affairs | 427.2k | N/A | 1965 |
Mr. Adrian K. Miller | VP of Investor Relations | N/A | N/A | N/A |
Mr. Shaun M. O'Neil | Chief Commercial Officer | N/A | N/A | N/A |
James Mitchell M.D. | VP of Digital Health | N/A | N/A | N/A |
Ms. Sunny Webb | VP, Data & Analytics | N/A | N/A | N/A |
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
PAVmed Inc.’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 4; Compensation: 10.